Bivalirudin
Back to searchMolecule Structure
Scientific Name
Bivalirudin
Description of the Drug
Bivalirudin is a direct thrombin inhibitor used to treat heparin-induced thrombocytopenia and to prevent thrombosis during percutaneous coronary intervention.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00006
http://www.drugbank.ca/drugs/DB00006
Brand Name(s)
Angiomax, Angiomax rtu, Bivalirudin, Bivalirudin in 0.9% sodium chloride
Company Owner(s)
Apotex Inc, Fresenius Kabi Usa Llc, Hainan Shuangcheng Pharmaceuticals Co Ltd, Sandoz Inc, Hospira Inc, Eugia Pharma Specialities Ltd, Accord Healthcare Inc, Dr Reddys Laboratories Ltd, Meitheal Pharmaceuticals Inc, Maia Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Thrombin | SINGLE PROTEIN | INHIBITOR | CHEMBL204 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL25739 | ||
| PharmGKB | PA10032 | ||
| DrugBank | DB00006 | ||
| PubChem: Thomson Pharma | 15363303 | 14891095 | |
| PubChem | 101041682 | 73952246 | 16129704 |
| Nikkaji | J1.204.802E | ||
| BindingDB | 50248103 | ||
| EPA CompTox Dashboard | DTXSID00155847 | ||
| DrugCentral | 385 | ||
| Brenda | 13504 | 151566 | 28560 |
| ChemicalBook | CB9471951 | ||
| Guide to Pharmacology | 6470 | ||
| rxnorm | ANGIOMAX | BIVALIRUDIN | BIVALIRUDIN TRIFLUOROACETATE |
| ChEBI | 59173 |
